Rabies Vaccine Market Expected to Reach $2 Billion by 2034

According to a new report published by Allied Market Research, titled “Rabies Vaccine Market," The rabies vaccine market size was valued at $1.3 billion in 2024 and is estimated to reach $2 billion by 2034, growing at a CAGR of 4.5% from 2025 to 2034.

Rabies is a zoonotic viral disease that causes encephalomyelitis in almost all warm-blooded animals, including humans. The causative agent is found in domestic and wild animals and is transmitted to other animals or humans through close contact with their saliva. The saliva is transmitted through bites, scratches, licks on broken skin, and mucous membranes. Rabies vaccine is an immunization used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus. Rabies vaccine is an inactivated virus vaccine prepared either in human diploid cell culture (HDCV) or in purified chick embryo cell culture (PCEC).

The rabies vaccine market growth is driven by a rise in the prevalence of rabies, an increase in the number of stray dogs in developing countries such as India, and the presence of major market players who manufacture rabies vaccines. In addition, the provision of high-quality vaccines by major market players is anticipated to fuel the growth of the rabies vaccine market size. For instance, Sanofi S.A., a pharmaceutical company, provides Imovax rabies vaccine, which is a sterile, stable, freeze-dried suspension of rabies virus, which is used as pre-exposure prophylaxis and post-exposure prophylaxis. The vaccine is used for post-exposure immunization and post-exposure prophylaxis of rabies.

In addition, a rise in the prevalence of rabies is anticipated to boost the growth of the rabies vaccine industry. For instance, according to a report shared by the Ministry of Health and Family Welfare, Government of India, in 2022, it was reported that an estimated 35172 human deaths (59.6% of global deaths) and loss of approximately 2.2 million disability adjusted life years occur per year in Asia due to dog-mediated rabies. India accounts for the most deaths in Asia (65% of human rabies deaths) and globally (36% of human rabies deaths).

In addition, a rise in initiatives taken by the governments is anticipated to boost the growth of the rabies vaccine market. For instance, in September 2023, the Tennessee Dept of Health and the U.S. Dept of Agriculture air-dropped oral rabies vaccine packets along Tennessee’s borders with Alabama, Georgia, North Carolina, and Virginia. Rabies Vaccine Market Outlook indicates steady expansion supported by rising vaccination coverage, stronger public-health commitments, and growing investments in localized production.

In addition, in September 2023, the Government of India and the United Nations Development Program (UNDP) partnered to strengthen the rabies control program. The Centre for One Health, under the Ministry of Health and Family Welfare’s National Centre for Disease Control (NCDC), requested the support of the UNDP in India to supplement its efforts to strengthen rabies prevention vaccine, and control through digitalization of rabies vaccinations. The digitalization process is expected to involve real-time monitoring of rabies vaccine stocks and tracking of beneficiaries, as well as ensuring that all doses of the rabies post-exposure prophylaxis regimen are administered. Anti-rabies vaccine demand continues to rise as countries intensify efforts to control human and animal rabies, supported by wider adoption of cost-efficient immunization protocols.

Moreover, R&D efforts have led to the creation of improved rabies vaccines, including new formulations and delivery methods. These advances make vaccination more accessible and effective. Thus, this factor is anticipated to boost the rabies vaccine industry. In addition, regulations governing pet vaccination and public health measures for rabies control drive demand for rabies vaccines within the veterinary and animal healthcare industries and foster the growth of the rabies vaccine market. Rabies Vaccine Market Trends increasingly highlight a transition toward more accessible, cost-efficient rabies immunization models as countries strengthen prevention programs in high-burden regions.

However, maintaining a consistent supply of vaccines, especially in remote or resource-constrained areas, is difficult. Vaccine storage and distribution infrastructure, if not adequate, can lead to vaccine shortages or spoilage. Thus, this factor is expected to hinder the growth of the rabies vaccine market. In addition, public health awareness campaigns and educational programs about rabies and the importance of vaccination have a significant impact on driving vaccine demand.

These campaigns aim to inform the public about the dangers of rabies and the necessity of vaccination. Therefore, this factor provides lucrative opportunities for the rabies vaccine market growth.

The rabies vaccine market is segmented on the basis of product type, prophylaxis type, application, end-user, and region. By product type, it is segmented into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine, human rabies immune globulin (HRIG), and others. By prophylaxis type, it is classified into pre-exposure prophylaxis and post-exposure prophylaxis. By application, it is segmented into human and animal. By end-user, it is segmented into hospitals, veterinary clinics, and others. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The human rabies immune globulin (HRIG) segment is expected to be the fastest growing segment during the forecast period, owing to the increase in awareness of the critical role HRIG plays in immediate post-exposure treatment is driving its demand, especially in areas where rabies exposure through dog bites is common. In addition, the replacement of equine-derived immunoglobulins with safer human-derived alternatives is fueling rabies vaccine market expansion worldwide.

By prophylaxis type, the pre-exposure prophylaxis segment is projected to be the fastest-growing segment during the forecast period owing to many countries promoting preventive vaccination for people who work closely with animals or live in areas where rabies is common. Moreover, the rise in international travel and pet ownership is encouraging more people to get vaccinated before potential exposure.

By application, the animal segment is projected to be the fastest-growing segment during the rabies vaccine market forecast, owing to governments and animal health agencies focusing on eliminating rabies at its source of infected animals. Many countries are enforcing mandatory vaccination policies for pets, especially dogs and cats, to prevent transmission to humans. However, the human segment held the major rabies vaccine market share in 2024.

By end user, the veterinary clinics segment is projected to be the fastest-growing segment during the forecast period, owing to pet owners becoming more conscious of the need for regular rabies vaccination to protect both animals and humans. Moreover, government laws in many countries mandate rabies vaccination for domestic pets, especially dogs and cats, which is increasing visits to veterinary clinics.

Region-wise, North America held the major rabies vaccine market Share in 2024 and is expected to maintain its lead during the forecast period, owing to the presence of large market players and highly developed healthcare infrastructure. However, the Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to a higher number of people getting exposed to bites or scratches from dogs or animals suffering from rabies and an increase in awareness among people regarding vaccination.

The key players profiled in the global rabies vaccine market analysis include Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA.

Key Findings of the Study

• By product type, the chick embryo cells rabies vaccine segment was the highest revenue contributor to the rabies vaccine market in 2024.
• By prophylaxis type, the post-exposure prophylaxis segment was the highest revenue contributor to the market in 2024.
• By application, the human segment was the highest revenue contributor to the market in 2024.
• By end user, the hospitals segment was the highest revenue contributor to the rabies vaccine market in 2024.
• Region-wise, North America was the highest revenue contributor in 2024.